What is the Ideal Technique for Testing the Biocompatibility of Peritoneal Dialysis Solutions?

T he past few years have seen significant advances in our understanding of the inflammatory proc esses that occur in the peritoneal cavity of patients being treated for end-stage renal failure with peritoneal dialysis. These investigations have confirmed the importance of the peritoneal membrane and the mesothelium, in particular, as a site for the production of mediators important in the activation and control of inflammation (1-3). While it is apparent that peritonitis is still the major problem associated with continuous ambulatory peritoneal dialysis therapy, it is also clear that structural and functional changes in the peritoneal membrane occur in its absence (4,5). This has strengthened the belief that other factors, in addition to infection, are responsible for the long-term loss of peritoneal membrane function. Over the past 15 years, since the publication of the seminal paper by Duweet al. (6), extensive research effort has been focused on the question of peritoneal dialysis fluid (PDF) biocompatibility and the effects of components of commercial PDF on cell viability and function. These experiments have been performed on many different cell populations including peripheral and peritoneal leukocytes, as well as the cells of the peritoneal membrane, both in viva and in vitro [see Jörres et al. (7) for review]. The sum of these observations suggests that conventional PDF has significant modulatory and in some cases toxic effects on peripheral and peritoneal cell function. Little is known, however, about the impact of long-term exposure of the peritoneum to PDF and how its function as a dialyzing organ is altered. The current review will examine the field of PDF biocompatibility testing. It will seek to address the following questions: (1) What are the current test systems? (2) Are these test systems clinically relevant? (3) How can we improve biocompatibility testing? (4) What do the results ofbiocompatibility testing mean?

[1]  D. Oreopoulos,et al.  Biocompatibility of peritoneal dialysis solutions. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[2]  T. Liberek,et al.  Effect of lactate-buffered peritoneal dialysis fluids on human peritoneal mesothelial cell interleukin-6 and prostaglandin synthesis. , 1995, Kidney international.

[3]  U. Frei,et al.  Peritoneal dialysis fluid biocompatibility: does it really matter? , 1994, Kidney international. Supplement.

[4]  N. Topley,et al.  Role of the peritoneal membrane in the control of inflammation in the peritoneal cavity. , 1994, Kidney international. Supplement.

[5]  M. Davies,et al.  The source and possible significance of hyaluronan in the peritoneal cavity. , 1994, Kidney international.

[6]  John D. Williams,et al.  Biocompatibility Studies on Peritoneal Cells , 1994, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[7]  A. Donker,et al.  Antibacterial peritoneal defence in automated peritoneal dialysis: advantages of tidal over continuous cyclic peritoneal dialysis? , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  N. Topley,et al.  In-vitro biocompatibility of alternative CAPD fluids; comparison of bicarbonate-buffered and glucose-polymer-based solutions. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[9]  T. Liberek,et al.  Peritoneal dialysis fluid inhibition of polymorphonuclear leukocyte respiratory burst activation is related to the lowering of intracellular pH. , 1993, Nephron.

[10]  A. Wieslander,et al.  Heat sterilized PD-fluids impair growth and inflammatory responses of cultured cell lines and human leukocytes. , 1993, Clinical nephrology.

[11]  A. Donker,et al.  Biocompatibility of a glucose-polymer-containing peritoneal dialysis fluid. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  A. Donker,et al.  In vivo exposure to the currently available peritoneal dialysis fluids decreases the function of peritoneal macrophages in CAPD. , 1993, Clinical nephrology.

[13]  T. Liberek,et al.  Peritoneal dialysis fluid inhibition of phagocyte function: effects of osmolality and glucose concentration. , 1993, Journal of the American Society of Nephrology : JASN.

[14]  T. Liberek,et al.  Impact of Peritoneal Dialysis Solutions on Peritoneal Immune Defense , 1993, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[15]  A. Donker,et al.  Peritoneal defense in continuous ambulatory versus continuous cyclic peritoneal dialysis. , 1992, Kidney international.

[16]  E. Köttgen,et al.  Inhibition of cytokine synthesis by peritoneal dialysate persists throughout the CAPD cycle. , 1992, American journal of nephrology.

[17]  A. Wieslander,et al.  Toxicity of peritoneal dialysis fluids on cultured fibroblasts, L-929. , 1991, Kidney international.

[18]  H. Verbrugh,et al.  Cytotoxic Effects of Commercial Continuous Ambulatory Peritoneal Dialysis (CAPD) Fluids and of Bacterial Exoproducts on Human Mesothelial Cells in Vitro , 1989, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[19]  A. Sheil,et al.  Peritoneal morphology on maintenance dialysis. , 1989, American journal of nephrology.

[20]  W. Malaisse,et al.  Crabtree effect in tumoral pancreatic islet cells. , 1988, The Journal of biological chemistry.

[21]  D. Lloyd,et al.  Host defence in continuous ambulatory peritoneal dialysis: the effect of the dialysate on phagocyte function. , 1986, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[22]  B. Canaud,et al.  Permanent loss of ultrafiltration capacity of the peritoneum in long-term peritoneal dialysis: an epidemiological study. , 1983, Nephron.

[23]  A. Duwe,et al.  Effects of the composition of peritoneal dialysis fluid on chemiluminescence, phagocytosis, and bactericidal activity in vitro , 1981, Infection and immunity.

[24]  D. H. Koobs Phosphate mediation of the Crabtree and Pasteur effects. , 1972, Science.